PTGS2 and neoplasm: Our studies demonstrated that treatment of one tumor resulted in increased growth of secondary tumor in a PAFR-dependent manner in a process blocked by systemic administration of antioxidants, cyclooxygenase type 2 (COX-2) inhibitors or depleting antibodies against Tregs (41, 42).